Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Site 601-020 (Part C), Brooklyn

Site 601-003 (Part C), Baltimore

Site 601-004 (Part C), Birmingham

Site 601-001 Healthy Volunteer Clinical Research Unit (Part A, B and D), Anniston

Site 601-019 (Part C), Lexington

Site 601-002 (Part C), Cincinnati

Site 601-023 (Part C), Troy

Site 601-013 (Part C), Greenfield

Site 601-017 (Part C), Fargo

Site 601-011 (Part C), St Louis

Site 601-006 (Part C), Overland Park

Site 601-010 (Part C), El Paso

Site 601-016 (Part C), Colorado Springs

Site 601-008 (Part C), Scottsdale

Site 601-007 (Part C), Encino

Site 601-015 (Part C), Upland

Site 601-014 (Part C), Bakersfield

Site 601-018 (Part C), Portland

Site 601-012 (Part C), Boston

Site 601-106 (Part C), Calgary

Site 601-103 (Part C), London

Site 601-107 (Part C), Niagara Falls

Site 601-108 (Part C), Toronto

Site 601-102 (Part C), Québec

Site 601-105 (Part C), Québec